GMAB
Genmab A/s Health Care Pharmaceutical Preparations Russell 3000
$57.06Close
$23.85 – $57.2952-week range
Nov 5, 2026Next report · before the open
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 98 · stronger than 98% of stocks over 12 months
- RS line at a 1-year high outperforming the S&P 500 more than at any point this year
- Near its high at its 52-week high
- Accumulation up-day volume 2.6× down-day volume over 50 sessions
Cautions
- Extended 12.5 ATR above its 50-day average
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Trade setup
ATR%
4.3%
$2.45 a day · 2×ATR $52.16
RS
98 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
2.1×
vs 50-day average
Up/down volume
2.56
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 8 of 8
Screen verdict
Not scorable — no annual report on file.
Filings
No readable filings.
Current reports
| Filed | Disclosed |
|---|---|
| Oct 28, 2026 | Foreign issuer report ↗ |
| Oct 23, 2026 | Foreign issuer report ↗ |
| Oct 13, 2026 | Foreign issuer report ↗ |
| Oct 7, 2026 | Foreign issuer report ↗ |
| Oct 5, 2026 | Foreign issuer report ↗ |
| Oct 2, 2026 | Foreign issuer report ↗ |
| Sep 29, 2026 | Foreign issuer report ↗ |
| Sep 24, 2026 | Foreign issuer report ↗ |
| Sep 9, 2026 | Foreign issuer report ↗ |
| Sep 9, 2026 | Foreign issuer report ↗ |
| Sep 8, 2026 | Foreign issuer report ↗ |
| Aug 12, 2026 | Foreign issuer report ↗ |